Published in Haemophilia on July 01, 2006
Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel. Blood (2012) 1.29
Platelet function tests: a comparative review. Vasc Health Risk Manag (2015) 1.11
Bleeding disorders in the tribe: result of consanguineous in breeding. Orphanet J Rare Dis (2010) 0.87
Kinetics and mechanics of clot contraction are governed by the molecular and cellular composition of the blood. Blood (2015) 0.85
Correction of murine Bernard-Soulier syndrome by lentivirus-mediated gene therapy. Mol Ther (2011) 0.83
What's new in using platelet research? To unravel thrombopathies and other human disorders. Eur J Pediatr (2007) 0.81
Strategies in Clinical and Laboratory Diagnosis of Inherited Platelet Function Disorders in Children. Transfus Med Hemother (2010) 0.80
Hematuria: an uncommon presentation of Glanzmann's thrombasthenia-lessons learnt. Indian J Urol (2010) 0.75
Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost (2006) 2.99
Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. J Lab Clin Med (1992) 2.22
Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg (1996) 2.11
Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost (2005) 1.83
A simple and effective approach for the treatment of chronic wound infections caused by multiple antibiotic resistant Escherichia coli. J Hosp Infect (2008) 1.71
Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol (1995) 1.55
Trajectory adaptation to a nonlinear visuomotor transformation: evidence of motion planning in visually perceived space. J Neurophysiol (1995) 1.54
Strong constraints on the rare decays B(s)(0) → μ+ μ- and B0 → μ+ μ-. Phys Rev Lett (2012) 1.50
First observation of the decays B(0) → D(+)K(-)π(+)π(-) and B(-) → D(0)K(-)π(+)π(-). Phys Rev Lett (2012) 1.50
Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med (1997) 1.45
Determination of the X(3872) meson quantum numbers. Phys Rev Lett (2013) 1.42
Liver transplantation in severe von Willebrand disease. Lancet (1991) 1.40
Refractory thrombocytopenia in a 27-year-old female following allogeneic bone marrow transplantation. Am J Hematol (1993) 1.40
Thrombophilia in sickle cell disease: the red cell connection. Blood (2001) 1.39
Frequency of factor V Arg506 Gln in Italians. Thromb Haemost (1996) 1.39
Decreased platelet expression of myosin regulatory light chain polypeptide (MYL9) and other genes with platelet dysfunction and CBFA2/RUNX1 mutation: insights from platelet expression profiling. J Thromb Haemost (2006) 1.35
Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost (2001) 1.34
Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation (1994) 1.28
Recommendations for the Standardization of Light Transmission Aggregometry: A Consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. J Thromb Haemost (2013) 1.25
First observation of CP violation in the decays of B(s)0 mesons. Phys Rev Lett (2013) 1.21
Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost (1997) 1.17
Acquired qualitative platelet disorders. Clin Haematol (1983) 1.13
Decreased expression of phospholipase C-beta 2 isozyme in human platelets with impaired function. Blood (1996) 1.13
Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. J Am Coll Cardiol (1987) 1.11
DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood (1984) 1.10
Reply to: 'the discovery of a new class of synaptic transmitters in smooth muscle fifty years ago and amelioration of coronary artery thrombosis'. Acta Physiol (Oxf) (2013) 1.09
Multicenter study of homocysteine measurement--performance characteristics of different methods, influence of standards on interlaboratory agreement of results. Thromb Haemost (2001) 1.08
Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation (1996) 1.08
Cirrhosis associated with multiple transfusions in thalassaemia. Arch Dis Child (1984) 1.07
Platelet coagulant activities in diabetes mellitus. Evidence for relationship between platelet coagulant hyperactivity and platelet volume. J Lab Clin Med (1984) 1.05
The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg (1997) 1.03
Platelet signal transduction defect with Galpha subunit dysfunction and diminished Galphaq in a patient with abnormal platelet responses. Proc Natl Acad Sci U S A (1997) 1.02
Mechanisms of platelet aggregation. Curr Opin Hematol (2001) 1.02
Increased fibrinopeptide A after prothrombin complex concentrates. Thromb Haemost (1980) 1.02
Abnormal inside-out signal transduction-dependent activation of glycoprotein IIb-IIIa in a patient with impaired pleckstrin phosphorylation. Blood (1996) 0.96
Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood (2000) 0.96
Production of a monoclonal antibody directed against the recombinant SEL1L protein. Int J Biol Markers (2002) 0.96
Measurement of form-factor-independent observables in the decay B0→K(*0)μ(+)μ(-). Phys Rev Lett (2013) 0.96
Observation of a resonance in B+ → K+ μ+ μ- decays at low recoil. Phys Rev Lett (2013) 0.95
Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet (1987) 0.95
Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol (1992) 0.95
Isolation of a pancreas-specific gene located on human chromosome 14q31: expression analysis in human pancreatic ductal carcinomas. Genomics (1997) 0.94
Triple nostrils: a case report and review. Br J Plast Surg (1987) 0.94
High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb (1994) 0.93
[Project, natural lighting and comfort indoor]. Ann Ig (2008) 0.92
Rare bleeding disorders. Haemophilia (2008) 0.92
Congenital disorders of platelet function. Semin Hematol (1986) 0.92
Bile lipid composition and haemostatic variables in a case of high density lipoprotein deficiency (Tangier disease). Eur J Clin Invest (1984) 0.91
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J (2013) 0.91
Mechanism of platelet factor 4 (PF4) deficiency with RUNX1 haplodeficiency: RUNX1 is a transcriptional regulator of PF4. J Thromb Haemost (2011) 0.90
von Willebrand disease: laboratory aspects of diagnosis and treatment. Haemophilia (2004) 0.90
Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost (2013) 0.90
Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis. Thromb Haemost (1986) 0.89
Risk of thromboembolic complications in patients with inflammatory bowel disease. Study of hemostasis measurements. Int J Clin Lab Res (1991) 0.89
Effect of heparin on the in vivo release and clearance of human platelet factor 4. Blood (1983) 0.89
Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery. J Thromb Haemost (2011) 0.89
Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation. Circulation (1990) 0.87
Evaluation of platelet function. Semin Hematol (1986) 0.87
Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. Thromb Haemost (1997) 0.87
Effect of platelet count on platelet aggregation measured with impedance aggregometry (Multiplate™ analyzer) and with light transmission aggregometry. J Thromb Haemost (2013) 0.86
Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. J Thromb Haemost (2007) 0.86
Integrilin prevents prolonged bleeding times after cardiopulmonary bypass. Ann Thorac Surg (1998) 0.86
Effect of calcium ion concentration on the ability of fibrinogen and von Willebrand factor to support the ADP-induced aggregation of human platelets. Blood (1987) 0.86
High-D-dimer plasma levels predict poor outcome in esophageal variceal bleeding. Dig Liver Dis (2008) 0.86
Early presence of activated ('exhausted') platelets in malignant tumors (breast adenocarcinoma and malignant melanoma). Eur J Cancer Clin Oncol (1989) 0.86
Secreted platelet proteins with antiheparin and mitogenic activities in chronic renal failure. J Lab Clin Med (1980) 0.85
Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol (1995) 0.85
Early growth response transcription factor EGR-1 regulates Galphaq gene in megakaryocytic cells. J Thromb Haemost (2006) 0.84
Changes of prothrombin fragment 1+2 (F 1+2) as a function of increasing intensity of oral anticoagulation--considerations on the suitability of F 1+2 to monitor oral anticoagulant treatment. Thromb Haemost (1998) 0.84
Risk management of HBsAg or anti-HCV positive healthcare workers in hospital. Dig Liver Dis (2001) 0.84
[A hyperhomocysteinemia study in a population with a familial factor for acute myocardial infarct and sudden cardiac death at a young age]. Cardiologia (1999) 0.84
Platelet function during cardiac operation: comparison of membrane and bubble oxygenators. J Thorac Cardiovasc Surg (1982) 0.84
Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential. J Thromb Haemost (2008) 0.83
Effect of ticlopidine on platelet aggregation, adherence to damaged vessels, thrombus formation and platelet survival. Thromb Res (1985) 0.83
Selective thrombin inhibitors: the next generation of anticoagulants. J Am Coll Cardiol (1993) 0.83
A baboon model for hematologic studies of cardiopulmonary bypass. J Lab Clin Med (1997) 0.83
First evidence for the decay B(s)(0)→μ+ μ-. Phys Rev Lett (2013) 0.83
Platelet survival and thrombosis. Arteriosclerosis (1983) 0.83
In vitro effect of fresh frozen plasma on the activated coagulation time in patients undergoing cardiopulmonary bypass. Anesth Analg (1988) 0.83
Usefulness of a flow cytometric analysis of intraplatelet vasodilator-stimulated phosphoprotein phosphorylation for the detection of patients with genetic defects of the platelet P2Y(12) receptor for ADP. J Thromb Haemost (2010) 0.83
An automatic contour propagation method to follow parotid gland deformation during head-and-neck cancer tomotherapy. Phys Med Biol (2011) 0.83
The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation. Thromb Haemost (1999) 0.83
Platelet secretion defect associated with impaired liberation of arachidonic acid and normal myosin light chain phosphorylation. Blood (1984) 0.82
Inhibition of thromboxane A2 synthesis in human platelets by coagulation factor Xa. Proc Natl Acad Sci U S A (1983) 0.82
Fibrinogen-independent aggregation and deaggregation of human platelets: studies in two afibrinogenemic patients. Blood (1987) 0.82
SEL1L, the human homolog of C. elegans sel-1: refined physical mapping, gene structure and identification of polymorphic markers. Hum Genet (2000) 0.82
Mapping the platelet proteome: a report of the ISTH Platelet Physiology Subcommittee. J Thromb Haemost (2005) 0.82
Platelet secretion defect in patients with the attention deficit disorder and easy bruising. Blood (1984) 0.82
Absence of hyperhomocysteinemia in ten patients with primary pulmonary hypertension. Thromb Res (1997) 0.82
Cardiac relapses in myeloid leukemia: case report and review of the literature. Pediatr Hematol Oncol (1987) 0.82
Measurement of the CP asymmetry in B(+)→K(+)μ(+)μ(-) decays. Phys Rev Lett (2013) 0.81
Human platelet aggregation and release reaction induced by platelet activating factor (PAF-acether)--effects of acetylsalicylic acid and external ionized calcium. Thromb Haemost (1985) 0.81
Desmopressin and blood loss after cardiac surgery. Lancet (1993) 0.81
APOE-491 promoter polymorphism is a risk factor for late-onset Alzheimer's disease. Neurology (1999) 0.81
Peripheral blood lymphocyte subpopulations in patients with viral warts. Acta Derm Venereol (1986) 0.81